Fibrates News and Research

RSS

Cholesterol lowering drugs do not appear to decrease the risk of melanoma

No clear evidence exists that some widely-prescribed cholesterol-lowering drugs can decrease the risk of melanoma, a deadly and malignant skin cancer, according to a new review of recent studies.

7 Nov 2005

Actos reduces the combined risk of non-fatal heart attacks, strokes in patients with type-2 diabetes

A study published in The Lancet shows that Takeda's Actos (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk of non-fatal heart attacks, strokes and deaths by an additional 16% on top of standard medication

10 Oct 2005

HDL cholesterol helps prevent blocked arteries and heart attack

Cardiology experts at Johns Hopkins have issued interim guidelines for physicians on how best to treat low levels of HDL cholesterol, the so-called good cholesterol, which helps keep arteries clear from the buildup of LDL cholesterol, the so-called bad cholesterol.

22 Sep 2005

Information about serious adverse effects of cerivastatin were known within months after drug launched

A review of the published literature and of internal company documents from the manufacturer of cerivastatin, a cholesterol lowering drug removed from the market in 2001, suggests that information about serious adverse effects of this medication was known to the company within months after this drug was launched

23 Nov 2004

Patients taking the lipid-lowering medications have a relatively low risk of developing rhabdomyolysis

Patients taking the lipid-lowering medications atorvastatin, pravastatin, and simvastatin to reduce cholesterol levels, have a relatively low risk of developing rhabdomyolysis, (a disorder that causes the breakdown of muscle), according to a new study in the December 1 issue of JAMA.

23 Nov 2004

Zetia co-administered with Fenofibrate significantly reduced LDL ("bad") cholesterol in mixed hyperlipidemia patients

Results from a new study showed that coadministration of Zetia (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apo B1 in patients with mixed hyperlipidemia and high LDL cholesterol when compared to fenofibrate alone.

9 Nov 2004

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.

4 Apr 2004

Fibrates News and Research

Cholesterol lowering drugs do not appear to decrease the risk of melanoma

Actos reduces the combined risk of non-fatal heart attacks, strokes in patients with type-2 diabetes

HDL cholesterol helps prevent blocked arteries and heart attack

Information about serious adverse effects of cerivastatin were known within months after drug launched

Patients taking the lipid-lowering medications have a relatively low risk of developing rhabdomyolysis

Zetia co-administered with Fenofibrate significantly reduced LDL ("bad") cholesterol in mixed hyperlipidemia patients

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News